The effects of thiabendazole, mebendazole and cambendazole in normal and immunosuppressed dogs infected with a human strain of Strongyloides stercoralis

Abstract

The effects of three benzimidazole anthelmintics in dogs infected with a human strain of Strongyloides stercoralis were investigated. Cambendazole, but not thiabendazole or mebendazole, abrogated the subsequent development of a patent infection when administered at the same time as infection to immunocompetent dogs. None of the drugs eradicated infection when given after the onset of patency in immunosuppressed animals, although worm burdens were greatly reduced in dogs treated with cambendazole. The implications of these findings for the treatment of patients with strongyloidiasis, particularly those with disseminated infections, are discussed.

Fenbendazole treatment of dogs with naturally acquiredStrongyloides stercoralisinfection

“…While a treatment schedule of 10 to 50 mg/kg fenbendazole for three days is recommended in some parasitological texts (Nolan 2001, Taylor and others 2007), fenbendazole is described as ineffective by others (Deplazes 2006). Although other benzimidazoles, such as thiabendazole, mebendazole and cambendazole, have been tested against strongyloidosis in dogs (Grove and Northern 1988), the authors are not aware of any published data on the efficacy of fenbendazole against S stercoralis . This short communication describes the use of fenbendazole to treat naturally acquired S stercoralis infections in dogs.…”

Strongyloides stercoralis

“…En la actualidad hay tres fármacos para manejar esta parasitosis: el albendazol, el tiabendazol y la ivermectina. Hace dos décadas se usó el cambendazol con resultados aparentemente buenos, pero se dejó de manufacturar por razones desconocidas 74 .…”